Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantMHN Tandem Transplant Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.MP.162

    Tandem Transplant

    Customize your policy alerts

    Sign up for mhn Policy CP.MP.162 alerts

    Get alerted when Policy CP.MP.162 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria and coverage guidance for planned sequential (tandem) high-dose therapy with hematopoietic cell transplant, primarily autologous transplants (and select autologous→allogeneic sequences) for specific malignancies; applies to members/enrollees of the payer.

    Policy Summary
    Payermhn
    PolicyTandem Transplant
    Policy CodePolicy CP.MP.162
    Change TypeMaterial revisions to contraindications and added autologous→allogeneic MM criteria
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization documenting diagnosis, absence of listed contraindications, and planned timing within six months for tandem HCT.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Updated verbiage I.3.b.ii., I.3.c.i. through iii., and I.A.3.d.; added substance use contraindication I.B.15; removed broader statement limiting indications (criteria IV).

    Replaced prior broad contraindications with a new, condensed contraindication list I.B.1 through I.B.6.

    Added requirements for tandem autologous followed by reduced-intensity allogeneic transplant from an HLA-identical sibling donor for untreated, newly diagnosed multiple myeloma when contraindications absent.

    Replaced prior broad contraindications (inadequate cardiac, renal, pulmonary, or hepatic function and significant, uncorrectable, life-limiting medical condition) with a new, more specific contraindication list addressing GFR, acute liver failure, acute renal failure, septic shock, active extrapulmonary or disseminated infection, active tuberculosis infection, HIV infection with detectable viral load, progressive cognitive impairment, and other severe uncontrolled medical conditions.

    Added substance use as a contraindication (I.B.15 previously; updated list replaced with new I.B.1–6 over time).

    Updated HIV-related criteria to include CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and current effective antiretroviral therapy (ART).

    6documented organ-function or comorbidity contraindication items (I.B.1-6)
    3primary diagnoses listed as medically necessary indications
    ≤6 momax interval between transplants
    7CPT/HCPCS codes referenced
    CD4>200HIV approval threshold

    Coverage Criteria for Tandem Hematopoietic Cell Transplant

    Tandem autologous transplant (medical necessity)

    Covered when ALL of the following are met:

    Primary diagnosis: Member/enrollee has one of: newly diagnosed or responsive multiple myeloma; testicular germ cell tumors (relapsed or refractory to a cisplatin-based regimen); high-risk neuroblastoma defined by staging and biologic features (see subcriteria).

    See I.A.1-3 for detailed neuroblastoma subcriteria (stage, age, MYCN amplification, diploidy, unfavorable histology).

    Planned nature and timing: Second course of high-dose therapy and hematopoietic cell transplant is planned prospectively and to occur within six months of the first transplant.within six months

    Policy distinguishes tandem from repeat HCT performed for relapse.

    Organ function and comorbidity status: Member/enrollee does not have significant dysfunction of a major organ system or severe comorbidities as specified in contraindications (eg, bilirubin > 2 mg/dL; INR > 1.6 unless on oral anticoagulants; EF < 45%; FEV1 ≤ 50% predicted; DLCO ≤ 60% predicted; inadequate performance status).see contraindications list

    See I.B. for full contraindication parameters.

    Sequential autologous then allogeneic transplant for newly diagnosed MM

    Covered when ALL of the following are met:

    Diagnosis: Untreated, newly diagnosed multiple myeloma.
    Donor and conditioning: Autologous transplant followed by an allogeneic transplant from an HLA-identical sibling donor with reduced-intensity conditioning.HLA-identical sibling; reduced-intensity conditioning

    Autologous→unrelated donor considered on a case-by-case basis.

    Contraindications absent: None of the contraindications listed in section I.B. are present.

    If contraindications are present, autologous→allogeneic sequence is not medically necessary per this criterion.

    Coverage conditional on meeting contraindication and HIV criteria

    Coverage for tandem transplant is subject to absence of contraindications and meeting disease-specific indications referenced in current guidelines and literature.

    Contraindications absent: Member must not have any of the specified contraindications (examples include: inadequate GFR per policy, acute liver failure, acute renal failure, septic shock, active extrapulmonary or disseminated infection, active tuberculosis infection, HIV infection with detectable viral load unless HIV-specific criteria met, progressive cognitive impairment, other severe uncontrolled medical condition, or active substance use).N/A

    Contraindication list condensed to I.B.1–6 in recent revisions; see policy section I.B. for full, current list.

    HIV-specific acceptance criteria (when applicable): If member has HIV infection, all of the following must be met: CD4 cell count > 200 cells/mm3; absence of active AIDS-defining opportunistic infection; member is currently on effective antiretroviral therapy (ART).CD4 > 200 cells/mm3

    These HIV-specific stipulations were added in the 02/24 review.

    The policy language previously included a numbered criterion (IV) stating that current evidence does not support tandem transplants for indications other than those listed. That broad exclusional statement has been removed in recent revisions; the policy now operationalizes coverage through the specified medical necessity criteria and a focused contraindication list rather than an overarching blanket exclusion. The change is documented in the policy revision history indicating removal of criteria IV and minor background edits with no change to the core indications.

    Earlier versions contained a general statement limiting coverage to only the indications listed, but that blanket exclusion language has been deleted. The revision history notes removal of the prior exclusionary statement and replacement of a longer contraindication list with a condensed, operational list (I.B.1–6); coverage determination is now driven by meeting the stated disease-specific indications and absence of the specified contraindications rather than by a standalone ‘‘only those indications’’ clause.

    The policy distinguishes a tandem transplant from a repeat transplant performed for relapse: a tandem transplant is a prospectively planned second course of high-dose therapy and HCT occurring within six months of the first, whereas a repeat HCT performed because of disease relapse is not considered a tandem transplant and is treated as a separate scenario that does not meet the tandem-transplant criteria.

    Recent document edits are described as minor background revisions that did not alter the medical necessity criteria. The revision history documents routine annual reviews and editorial updates (for example, age-related wording changes and background updates) while confirming that core coverage criteria remain in effect.

    Candidate Indications and Disease-Specific Criteria

    Candidate indications

    Candidates for tandem autologous transplant include patients with:

    Multiple myeloma: Newly diagnosed or responsive multiple myeloma. Consider tandem transplant for patients not achieving at least a very good partial response (VGPR) after first autologous HCT and for those with high-risk features; collect sufficient stem cells for two transplants per guideline recommendations.

    NCCN recommends collecting enough hematopoietic stem cells for two transplants in eligible patients.

    Testicular germ cell tumors: Relapsed testicular cancer or tumors refractory to cisplatin-based regimens; high-dose chemotherapy with autologous SCT (single or tandem) is an accepted option.

    Background and guideline references support use in relapsed/refractory germ cell tumors.

    High-risk neuroblastoma: High-risk disease per specified staging, age, and biologic features (see I.A.3 a-d); tandem ASCT has shown improved event-free survival in trials for selected pediatric patients.

    Contraindications and Factors that May Lead to Denial

    The policy specifies an operational list of contraindications that, if present, may lead to denial of medical necessity for a planned tandem hematopoietic cell transplant. Key laboratory and clinical thresholds include: bilirubin > 2 mg/dL (hepatic dysfunction); INR > 1.6 (unless the member is on oral anticoagulants); and cardiac ejection fraction (EF) < 45% on MUGA or echocardiogram. Pulmonary criteria that can disqualify a candidate include FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted. Performance-status thresholds that can disqualify are Karnofsky/Lansky < 70% or ECOG > 2, and uncontrolled or disseminated infection is also a contraindication.

    The policy also operationalizes a broader set of clinical states that may preclude approval: acute liver failure; acute renal failure; septic shock; active extrapulmonary or disseminated infection (including active tuberculosis); progressive cognitive impairment; other severe uncontrolled medical conditions; and substance use. In addition, the revised contraindication framework references renal function limits (GFR below policy-specified thresholds) as exclusionary when documented.

    For members with HIV, the policy specifies conditions under which transplantation may still be considered: the member must meet all three HIV-specific acceptance criteria — CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and being currently on effective antiretroviral therapy — otherwise HIV with a detectable viral load is a contraindication.

    Operationally, the presence of any of the above-listed contraindications should be documented in the medical record and will be reviewed during prior authorization and coverage verification. Providers should supply relevant laboratory results, imaging reports (e.g., MUGA/echocardiogram, pulmonary function testing), performance-status assessments, and evidence of infection evaluation to demonstrate absence of disqualifying conditions prior to approval.

    This contraindication list replaced earlier, broader language and is intended to be applied consistently with clinical judgment, guideline-referenced standards, and any applicable regulatory requirements. When there is uncertainty or the member’s status is borderline, reviewers should confirm that all required documentation and evaluations have been submitted and consider case-by-case review as noted in the policy.

    Coding Implications and Clinical Thresholds

    Referenced CPT/HCPCS codesmixed
    38205Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
    38206Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
    38230Bone marrow harvesting for transplantation; allogeneic.
    38232Bone marrow harvesting for transplantation; autologous.
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition.
    ICD-10ICD-10
    No codes listed
    inv-10: Interval between first and second transplant — maximum planned interval
    Maximum planned intervalSecond course of high-dose therapy and HCT must be planned to occur within six months of the first transplant
    Planned vs repeat HCTTandem transplant must be prospectively planned rather than performed because of relapse
    Documentation expectationTransplant center records should support that the second transplant was planned within the six-month interval
    inv-11: Cardiac ejection fraction — EF threshold used to disqualify
    Ejection fraction cutoffMultigated acquisition (MUGA) scan or echocardiogram ejection fraction (EF) < 45% disqualifies the member from tandem transplant
    Assessment modality

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior authorization required for tandem HCT

    Prior authorization is required for tandem autologous transplant; requests must demonstrate the member meets all listed medical necessity criteria including eligible diagnosis, absence of contraindications, and that the second transplant is planned within six months.

    • Provide diagnosis supporting one of the covered indications (e.g., newly diagnosed or responsive MM, testicular GCT, high-risk neuroblastoma).
    • Document absence of contraindications in section I.B.
    • Document that the second transplant is planned prospectively and to occur within six months of the first transplant.
    Prior Authorization

    Verify coverage and applicable NCD/LCD prior to authorization

    Reviewers and providers should verify that prior authorization and any approval are consistent with the member's plan coverage and applicable Medicare/Medicaid NCDs or LCDs before proceeding with tandem transplant services.

    • Confirm consistency with the member's evidence of coverage, certificate of coverage, or plan contract terms.

    Evaluation and Pre-Transplant Assessment

    Documentation Required

    Pre-authorization evaluation requirements

    Evaluation required prior to authorization should include assessment of organ function (liver, cardiac, pulmonary), performance status, infectious disease evaluation, and documentation of stem cell collection/mobilization to establish eligibility for tandem transplant.

    • Liver: bilirubin and other relevant hepatic assessments.
    • Cardiac: MUGA or echocardiogram with ejection fraction.
    • Pulmonary: FEV1 and DLCO with percent predicted values.
    • Performance status: Karnofsky/Lansky or ECOG score.
    • Documentation of stem cell collection/mobilization and induction therapy response.

    Definitions and Background

    A tandem transplant is defined as a planned second course of high-dose therapy with hematopoietic cell transplant performed within six months of the initial transplant, prospectively scheduled to deepen and prolong response. Peripheral blood hematopoietic stem cells are collected and reserved to permit the second planned procedure.

    inv-26: Tandem transplant definition (short) — planned second course within six months
    Short definitionA planned second course of high-dose therapy and hematopoietic cell transplant occurring within six months of the first
    Prospective planningSecond transplant must be prospectively planned (not performed for relapse)
    Also calledAlso referred to as sequential or double transplant
    inv-27: Tandem transplant definition (alternate phrasing) — sequential high-dose chemo with stem cell rescue examples
    Alternate phrasing

    Post-Transplant Services and Global Billing

    inv-33: Global transplant services — harvesting, transplantation, related complications, pre/post care and S2150 reference
    Services includedGlobal transplant services encompass harvesting, transplantation, related complications, and pre/post-transplant care as defined in HCPCS S2150
    S2150 descriptionS2150 covers bone marrow or blood-derived stem cells harvesting, transplantation, related complications, pheresis and cell preparation/storage, marrow ablative therapy, drugs, supplies, hospitalization with outpatient follow-up, and number of pre/post-transplant care days in the global definition
    Billing guidanceProfessional coding guidance (CPT/HCPCS listed) should be consulted prior to claims submission
    inv-34: Post-transplant services — alignment with plan terms and NCDs/LCDs; consult full policy and CMS guidance
    Alignment with plan termsPost-transplant coverage and follow-up should align with the Health Plan's coverage documents and applicable NCDs/LCDs

    Transplant Center and Accreditation Considerations

    Note

    Center and facility expectation for tandem HCT

    Tandem transplants should be performed at appropriately accredited transplant centers; the policy implies care by experienced transplant centers and references standards of practice and coding guidance.

    • Ensure procedures are performed at a transplant center with relevant experience and appropriate accreditation.
    • Follow center policies consistent with standards of practice and coding guidance.
    Policy Summary
    Payermhn
    PolicyTandem Transplant
    Policy CodePolicy CP.MP.162
    Change TypeMaterial revisions to contraindications and added autologous→allogeneic MM criteria
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization documenting diagnosis, absence of listed contraindications, and planned timing within six months for tandem HCT.
    SourceLink
    On This Page
    Coverage Criteria for Tandem Hematopoietic Cell TransplantCandidate Indications and Disease-Specific CriteriaContraindications and Factors that May Lead to DenialCoding Implications and Clinical ThresholdsProvider Actions, Documentation, and AuthorizationEvaluation and Pre-Transplant AssessmentDefinitions and BackgroundPost-Transplant Services and Global BillingTransplant Center and Accreditation Considerations

    Randomized trials reported improved EFS with tandem consolidation in high-risk neuroblastoma.

    Disease-specific indications (referenced)

    Indications and supporting evidence are referenced for specific malignancies.

    Evidence and guideline references: Policy references literature and guideline sources supporting tandem transplant use for multiple myeloma, high-risk neuroblastoma, and testicular/germ cell tumors (including systematic reviews, randomized trials, and guideline documents such as NCCN, COG, and ASBMT).N/A

    See reference list for specific citations (e.g., Dhakal et al., Park et al., COG studies, NCCN testicular cancer guidance).

    Denial Risk

    Contraindications that may lead to denial — major organ dysfunction or severe comorbidity

    Presence of significant organ dysfunction or severe comorbidities listed in the policy contraindications may result in denial of medical necessity for a tandem transplant. Examples include: total bilirubin > 2 mg/dL; INR > 1.6 (unless on oral anticoagulants); cardiac ejection fraction < 45% on MUGA or echocardiogram; FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted; and performance status below thresholds (Karnofsky/Lansky < 70% or ECOG > 2).

    • Bilirubin > 2 mg/dL
    • INR > 1.6 (unless on oral anticoagulants)
    • Cardiac EF < 45% on MUGA or echocardiogram
    • Pulmonary: FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted
    • Performance status: Karnofsky/Lansky < 70% or ECOG > 2
    • Uncontrolled or disseminated infection
    Denial Risk

    Contraindications that may lead to denial — specified clinical states

    The presence of any of the policy’s specified contraindications may lead to denial of coverage for a tandem transplant; the updated contraindication list includes renal, hepatic, infectious, HIV- and cognition-related, and other severe uncontrolled conditions. Providers must confirm absence of these conditions when requesting approval.

    • GFR below the policy-specified threshold (as operationalized in the contraindication list)
    • Acute liver failure or acute renal failure
    • Septic shock
    • Active extrapulmonary or disseminated infection, including active tuberculosis
    • HIV infection with detectable viral load (unless HIV-specific criteria met: CD4 > 200 cells/mm3, no active AIDS-defining opportunistic infection, and on effective ART)
    • Progressive cognitive impairment or other severe uncontrolled medical condition
    • Active substance use (noted in prior revisions and encompassed by the consolidated contraindications)
    CD4 cell count — HIV-related approval threshold used as a key criterion
    HIV-related CD4 thresholdCD4 cell count > 200 cells/mm3 is required for HIV-positive members to be eligible for tandem transplant.
    HIV opportunistic infection requirementAbsence of active AIDS-defining opportunistic infection is required for HIV-positive members.
    ART requirementMember/enrollee must be currently on effective antiretroviral therapy (ART).
    Context in policy revisionsThese HIV-specific acceptance criteria were added in the 02/24 annual review and incorporated into the contraindication/acceptance section of the policy.
    Interaction with contraindicationsHIV infection with detectable viral load remains a contraindication unless the member meets the HIV-specific criteria above.
    EF should be measured by MUGA or echocardiogram as specified in policy
    Denial riskSignificant cardiac dysfunction (EF <45%) may trigger denial of medical necessity
    inv-12: Bilirubin — hepatic dysfunction threshold
    Total bilirubin threshold> 2 mg/dL indicates hepatic dysfunction and disqualifies the member from tandem transplant
    ContextHepatic dysfunction is listed among major organ system dysfunctions that preclude eligibility
    Denial implicationPresence of bilirubin >2 mg/dL can trigger denial of medical necessity
    inv-13: INR — coagulation threshold (with anticoagulant exception)
    INR threshold> 1.6 disqualifies the member from tandem transplant (exception: if on oral anticoagulants)
    Exception detailINR >1.6 is not disqualifying when elevated due to therapeutic oral anticoagulation
    Clinical impactAbnormal hemostasis per this INR threshold is included among contraindications that may lead to denial
    inv-14: Pulmonary function — FEV1/DLCO thresholds
    FEV1 thresholdForced expiratory volume in 1 second (FEV1) ≤ 50% of predicted value disqualifies the member
    DLCO thresholdDiffusing capacity of the lung for carbon monoxide (DLCO) ≤ 60% of predicted value disqualifies the member
    Pulmonary dysfunction implicationSpecified pulmonary function limits are operational contraindications and may lead to denial
    inv-15: Performance status — Karnofsky/Lansky/ECOG thresholds
    Performance status cutoffsKarnofsky or Lansky score < 70% OR ECOG performance score > 2 disqualifies the member
    Assessment scalesUse Karnofsky/Lansky for pediatric/functional scoring and ECOG for adult performance assessment
    Denial riskPerformance scores below these thresholds are listed among conditions that may trigger denial
  1. For Medicare members, review applicable NCDs/LCDs before applying policy criteria.
  2. Note

    Treatment sequencing must be prospectively planned and justified

    The policy requires that tandem transplants be planned prospectively (not as repeat HCT for relapse); clinical rationale and trial evidence inform decisions about single versus tandem strategies and should be documented when seeking approval.

    • Document indication-specific rationale (e.g., failure to achieve VGPR after first autologous HCT in MM or high-risk neuroblastoma trial data).
    • Evidence cited (StaMINA and other trials) may be used to support the planned sequencing.
    Step Therapy

    No explicit step therapy algorithm specified

    No formal step therapy algorithm is provided in this policy for sequencing transplants; clinical references discuss choice between single and tandem transplant approaches but the policy does not mandate stepwise prior treatments.

    • Policy emphasizes prospective planning of tandem transplant rather than a step-therapy sequence.
    • Literature references discuss comparative trial outcomes informing clinical choice.
    Documentation Required

    Expected clinical and procedural documentation for tandem HCT

    When submitting for authorization or documentation, include clinical and procedural records such as stem cell collection/mobilization details, records of induction therapy and response, and transplant center operative and follow-up records supporting the planned second transplant within six months.

    • Peripheral blood HSC collection/mobilization notes (timing and yield).
    • Induction therapy regimen and documented response (e.g., VGPR status).
    • Transplant center records demonstrating planned second preparative regimen and schedule within six months.
    Documentation Required

    Document clinical justification and follow regulatory/plan requirements

    Providers must document clinical justification and relevant evaluations consistent with standards of practice and applicable plan and regulatory requirements; state Medicaid or Medicare NCD/LCD requirements may supersede this policy.

    • Retain documentation of evaluations used to establish absence of contraindications and to justify the tandem approach.
    • Follow any state Medicaid or Medicare NCD/LCD requirements that may affect documentation or coverage.
    Denial Risk

    Denial risk reminder — organ dysfunction/comorbidity

    Presence of significant organ dysfunction or severe comorbidities listed in contraindications may lead to denial; ensure pre-authorization documentation addresses these specific contraindications and relevant labs/imaging.

    • Include recent labs (bilirubin, INR), cardiac EF assessment, and pulmonary function tests when applicable.
    • Document performance status and infection evaluations to demonstrate exclusion of contraindications.
    Denial Risk

    Denial risk reminder — specified contraindications

    Specified contraindications such as acute organ failure, septic shock, active disseminated infections, HIV with detectable viral load, progressive cognitive impairment, and other severe uncontrolled conditions can result in denial; verify and document absence of these states.

    • Confirm absence of acute liver or renal failure and septic shock.
    • Confirm no active extrapulmonary or disseminated infection or active tuberculosis.
    • If HIV-positive, document whether viral load is detectable or if HIV-specific criteria are met (see policy).
    Sequential high-dose chemotherapy with repeated hematopoietic stem cell rescue (e.g., two planned autologous transplants or autologous then allogeneic)
    ExamplesUsed as consolidation therapy in select malignancies such as high-risk neuroblastoma and multiple myeloma per cited trials and reviews
    TerminologyAlso described in literature as tandem autologous/reduced-intensity conditioning allogeneic sequences in comparative studies
    CMS guidanceFor Medicare members, review applicable Medicare NCDs, LCDs, and Coverage Articles before applying this clinical policy
    Consult full policyRefer to the full clinical policy and CMS guidance for Medicare requirements and potential plan-level variations in post-transplant service coverage